The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: You did referenced Pegfilgrastim, I mean that could potentially be a fairly -- I won't say eminent, but a launch. You have the PDUFA date (multiple
speakers) in September, as well as depending when you might launch in terms of the 180-day waiting period, which is in front of the Supreme
Court. The IP there, it's a little -- pathway has been a little -- there have been others who have gone through it to give a little bit more of a roadmap.
I mean, are you at the point to start thinking about your commercial strategy with that product?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: And then just, along those lines. I mean, the evolution of the commercial model, you also referenced 40% non-generics. You're already even ahead
of a potential action on Wixela on with -- you have Perforomist, which is actually a nice little product, you have the Dymista from Meda and then
you have -- I think you hope to have (inaudible) coming upstream as well. So, how should we think about the sales capacity and the go-to-market
approach there? Should people start to think about Mylan has a little bit more of commercial presence than what you've historically had in US
market?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: And then, do you have a significant interest on the specialty side to start to expand your therapeutic areas or should we think about you primarily
staying focused on respiratory?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: And then, how should we think about the Company's appetite for capital deployment. Also, given the fact that you are still digesting the Meda
transaction, paying down some of the near term debt that you took on from there. Talk a little bit about the flexibility and the firepower that you
have over the next 12 months to 18 months?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: And then, one of the deals, sort of small deals that I think had a lot of, Heather referred to it a couple of times and with the cold-eeze transaction
maybe -- should we be thinking about that as a steady stream of opportunities that you're going to be looking at?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: And then, what would it take to necessarily have you take a look at something more significant in size?
Question: Douglas Tsao - Barclays Capital, Inc. - Analyst
: Okay, great. Thank you very much Ken. I think we'll go across for a breakout.
| 
